View Older Stories
-
Veru partners with Novo Nordisk for obesity drug combination study
-
Bernstein says this cheap EU pharma stock is "a value trap"
-
Novo Nordisk targets two-thirds cut in drug launch times with AI
-
Novo Nordisk receives EU committee recommendation for oral Wegovy pill
-
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK200 at Bernstein SocGen Group, 'why's it still a value trap in our view'
-
FDA Commissioner Marty Makary to step down - Politico
-
Novo Nordisk's Wegovy shows 21% weight loss regardless of response speed
-
Novo Nordisk presents data on higher-dose Wegovy weight loss effects
-
TD Cowen on Novo Nordisk (NVO): 'Meet Management Highlights Multiple NearTerm Opportunities'
-
Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy
-
Novo Nordisk Eyes Large-Scale M&A Following Pfizer's Metsera Win - Semafor
-
Novo sees generic Ozempic delayed in China until next year - Bloomberg
-
Novo Nordisk (NVO) Misses Q1 EPS by 33c
-
Novo Nordisk reports Q1 earnings on Wednesday: Analysts flag key focus topics
-
Novo Nordisk (NVO) call put ratio 2.3 calls to 1 put with a focus on May 8 weekly options into quarter results
-
Novo Nordisk (NVO) call put ratio 3.4 calls to 1 put with a focus on September 35 calls into quarter results
-
Why Eli Lilly stock is down 3% today: FDA adverse event data explained
-
Novo Nordisk rebrands diabetes tablet as Ozempic in US
-
Lilly's Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays
-
FDA proposes to exclude semaglutide, tirzepatide from compounding list
-
Novo Nordisk gets FDA fast track status for ATTR heart disease drug
-
Morgan Stanley Comments on Eli Lilly (LLY) Amid Premarket Volatility
-
Hims & Hers expands platform to include Eli Lilly weight loss medications
-
Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage
-
Eli Lilly and Novo Nordisk shares fall as CVS opts out of Medicare obesity drug coverage
-
CVS Health Opts Out Of Medicare Obesity Drug Coverage Model
-
Walmart expands weight management services with virtual care platform
-
Novo Nordisk (NVO) PT Lowered to $36 at BMO Capital
-
Novo Nordisk launches higher-dose Wegovy for weight management
-
Novo Nordisk repurchases 805,000 B shares worth DKK 186.5 million
-
Novo Nordisk says Wegovy pill shows greater weight loss than Lilly rival
-
Novo Nordisk (NVO) call put ratio 1.2 calls to 1 put
-
LifeMD launches Novo Nordisk Wegovy subscription program
-
Novo Nordisk launches discounted Wegovy subscription plan in US
-
Novo Nordisk cuts Ozempic and Wegovy prices up to 48% in India
-
Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
-
BMO Capital Checking In With Novo Nordisk (NVO) Ahead of 1Q26
-
Should you buy the dip in Novo Nordisk stock? Wall Street analyst answers
-
Canaccord on Hims and Hers (HIMS): 'Novo partnership goes live; near-term headwind to revenue, long-term tailwind to the story'
-
Wolfe Research Starts Novo Nordisk (NOVOB:DC) (NVO) at Peerperform, 'no longer an obesity darling'
-
Novo Nordisk (NVO) call put ratio 1.5 calls to 1 put
-
India's Eris Lifesciences launches generic semaglutide at $13.8 per month
-
Novo Nordisk gets FDA approval for higher-dose Wegovy HD weight-loss drug
-
Bernstein SocGen Group Starts Novo Nordisk (NOVOB:DC) (NVO) at Underperform
-
HIMS to offer Wegovy and Ozempic through partnership with Novo Nordisk
-
Leerink on Structure Therapeutics (GPCR): 'Oral GLP-1 Achieves Best-In-Class Weight Loss'
-
Hims shares set for best week on record after new Novo Nordisk deal
-
Novo Nordisk issued FDA warning letter over adverse event reporting
-
BMO Capital Shares Thoughts on Novo Nordisk (NVO) Following The Hims Agreement
-
Novo Nordisk downgraded as pipeline 'not poised to blunt semaglutide LOE'

